MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Merck & Co Inc.

Uždarymo kaina

SektoriusSveikatos priežiūra

87.05 -2.91

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

86.61

Max

89.64

Pagrindiniai rodikliai

By Trading Economics

Pajamos

583M

3.7B

Pardavimai

-1B

16B

P/E

Sektoriaus vid.

13.696

73.239

Pelnas, tenkantis vienai akcijai

1.72

Dividendų pajamingumas

3.51

Pelno marža

23.963

Darbuotojai

73,000

EBITDA

1.3B

6.9B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+24.41% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.51%

3.06%

Kitas uždarbis

2025-04-24

Kitas dividendų mokėjimo data

2025-04-07

Kita Ex Dividend data

2025-06-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-19B

233B

Ankstesnė atidarymo kaina

89.96

Ankstesnė uždarymo kaina

87.05

Naujienos nuotaikos

By Acuity

37%

63%

123 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Merck & Co Inc. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-04 12:33; UTC

Uždarbis

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

2025-02-04 11:57; UTC

Uždarbis

Merck 4Q Sales Increase Results in Swing to Profit

2025-03-24 05:00; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

2025-03-05 19:42; UTC

Svarbiausios naujienos

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

2025-03-05 10:30; UTC

Svarbiausios naujienos

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

2025-02-05 12:00; UTC

Svarbiausios naujienos

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

2025-02-04 14:48; UTC

Uždarbis

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

2025-02-04 11:51; UTC

Uždarbis

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

2025-02-04 11:50; UTC

Uždarbis

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

2025-02-04 11:31; UTC

Uždarbis

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

2025-02-04 11:31; UTC

Uždarbis

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

2025-02-04 11:31; UTC

Uždarbis

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

2025-02-04 11:31; UTC

Uždarbis

Merck 4Q Januvia/Janumet Sales $487M >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck 4Q Keytruda Sales Up 19% >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck 4Q Keytruda Sales $7.84B >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck 4Q Pharmaceutical Sales Up 7% >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck 4Q Pharmaceutical Sales $14.04B >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck Sees FY Adj EPS $8.88-Adj EPS $9.03 >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck: Anticipate Strong Growth in Back Half of 2025, as Well as in Both 2026 and 2027 >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck Sees FY Rev $64.1B-$65.6B >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck: Believe Temporary Pause Will Facilitate a More Rapid Reduction of Excess Inventory >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck: Expect Strength in Oncology and Contributions From Ongoing and New Launches of Important Products in Both Human and Animal Health Businesses to More Than Offset GARDASIL Headwind >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck 4Q Adj EPS $1.72 >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck: Gardasil Market Dynamics in China Do Not in Any Way Diminish the Confidence Co. Has in the Business >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck 4Q Net $3.74B >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck: Excluding Sales of Gardasil in China in Both 2024 and 2025, Expect Strong 2025 Growth Between 7%-9% (Ex-FX) Driven by Continued Strength in Oncology and Animal Health as Well as Contributions From New Product Launches >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck: Sales Outlook Reflects Reassessment of Market for Gardasil/Gardasil 9 in China and Decision to Temporarily Pause Shipments Until at Least Mid-Year >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck Sees FY25 Sales $64.1B-$65.6B >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck: Decline in 4Q Januvia/Janumet Sales Primarily Due to Lower Pricing in U.S., and Ongoing Generic Competition in Many International Markets and Supply Constraints in China >MRK

2025-02-04 11:30; UTC

Uždarbis

Merck 4Q Winrevair Sales $200M >MRK

Akcijų palyginimas

Kainos pokytis

Merck & Co Inc. Prognozė

Kainos tikslas

By TipRanks

24.41% į viršų

12 mėnesių prognozė

Vidutinis 111.67 USD  24.41%

Aukščiausias 138 USD

Žemiausias 95 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Merck & Co Inc. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

17 ratings

11

Pirkti

6

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

89.32 / 93.08Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

123 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.